"The global life science's technology market is growing significantly, but it's especially exciting to watch the momentum on the West Coast. West Coast biotechs are rapid adopters of clinical trial technology, decentralized trial models and smaller, more focused outsourced providers like eClinical's Data Services" Biocom California, the association representing the California life science industry, reports that the state's life science sector has tripled since 2000, with a compound annual average growth rate of 5.6%. The organization's recent report also reveals that the local life science industry generated $131 billion in 2020 alone. Simultaneously with this growth, companies face increasing pressure in a crowded market to quicken drug development timelines to get treatments produced faster than competitors and contribute to the industry's sizable ascent. The elluminate Clinical Data Cloud, which now includes risk-based quality management (RBQM) for operational insights, and a Statistical Computing Environment (SCE) will help these companies enhance their clinical trial efficiencies through greater automation of processes delivering sustained competitive advantage.

The developed world is on the cusp of turning the corner in the fight against COVID-19 thanks to the unprecedented effort to rapidly develop and distribute effective vaccines. Now technologists are hoping to take drug development to the next level, and AI will play a big role. One of the companies at the forefront of using machine learning and AI to develop drugs is CytoReason. The company helps pharmaceutical firms like Pfizer accelerate drug development by providing high resolution models of the human body that's infected with the disease that the drug companies are targeting. "If I told you that in 200 years, drugs would be developed in a computer, you would not be real surprised," said CytoReason CEO and founder David Harel.